Shorts

Why We Need Expanded Access

Seltorexant vs Quetiapine Adjunct for MDD

What Makes This ADHD Drug Potentially Unique

The Biggest Challenge in Treating Alzheimer Disease

Morning Coffee and Updates: The Approval of Centanafadine for ADHD

Impact of Placebo & Patient Expectations on Medication Outcomes

Is Alzheimer Disease Actually Type 3 Diabetes?

Late Responders in Long Term Treatment With Austedo for Tardive Dyskinesia

The Placebo Effect at Work in Psychopharmacology

FDA Approves Centanafadine: A New Frontier in ADHD Treatment

Expanding the Neurotransmitter View of Depression

Discussing LAIs Candidly With Patients

COMP360, Synthetic Psilocybin, Shows Enduring Benefit

Financial Barriers to Neuromodulation Access

Impacts of Tribalism in Psychiatry

Mental Health Awareness & Advancing Cholinergic Agents

Barriers to Access in Postpartum Care

Assisting Treatment Outside of Psychiatric Care

Zolpidem Slows Alzheimer Progression in Animal Studies

Utilizing AI in Assessing Diagnosis

AI in Health Records & Scribe Notes

Circadian Components of Psychiatric Disorders

Bidirectionality of Sleep Quality and Waking Function

Positive Alixorexton Data In Narcolepsy

Links Between Sleep Health and Falls In Older Adults

Morning Coffee and Updates: Orexin 2 Receptor Agonists at SLEEP 2026

Relationship of REM Sleep and Depression

Predictors of Suicidality in Adolescents

Predicting Depression From Sleep Data Via Machine Learning

Do Hormonal Contraceptives Affect Sleep?